



# ISPOR

*Improving healthcare decisions*

## **Chapter Name**

**President**

**President-Elect**

**Past President**

**Secretary**

**Treasurer**

**When are elections held for your Chapter's Board?**

**Regional Chapter Members - 2017**

**Regional Chapter Members - 2016**

**Notes re Chapter members**

**Full ISPOR members (those paying dues to ISPOR Headquarters)**

**Does your Chapter collect membership dues or fees from individuals for local Chapter membership?**

**Benefits Chapter offer to members**

**Chapter's accomplishments in 2017 with regard to membership recruitment, retention, and engagement.**

**Academia%**

**Government/HTA Agency%**

**Industry - Pharmaceutical/Medical Device/Diagnostics/ Biotech%**

**Consulting%**

**Clinicians%**

**Student%**

**Other%**

**Chapter's accomplishments in 2017 with regard to education and training.**

**Chapter's accomplishments in 2017 with regard to research.**

**Chapter's accomplishments in 2017 with regard to policy-related activities.**

**Chapter's accomplishments with regard to Chapter meetings, workshops, or conferences in 2017.**

**Articles published in ISPOR's publication in 2017 - *Value in Health*, *Value in Health Regional Issues*, *Value and Outcomes Spotlight*, and ISPOR Regional newsletters by members in your Chapter.**

## **Macedonia**

Prof. Ljubica Shuturkova

Prof. Zoran Sterjev

Prof. Ljubica Shuturkova

Prof. Rubin Zareski

Prof. Katerina Ancevska Netkovska

26.03.2015

65

71

30

No

Education and professional development

60

15

15

10

10

5

HTA training for needs of the government (Drug Agency and Health Insurance Fund) - twice in year (April and September).

3 research projects in collaboration with pharmaceutical industry and physicians from the University Clinical Center.

- Participation in development of guidelines for therapeutic use of biosimilars. - Changes in Law for drugs and medicinal devices in part for parallel import of drugs.

**Contributions to ISPOR Conferences and Events by Chapter members in 2017. Include workshops, poster, and podium sessions.**

7th Adriatic and 5th Croatian Congress of Pharmacoeconomics and Outcomes Research, Poreč, Croatia, April 20-23, 2017 - Stevce Acevski (mk): Cost of illness – Antibiotic treatment of nosocomial infections from methicillin resistant staphylococcus aureus, accinetobacter sp. or pseudomonas aeruginosa - Aleksandra Kapedanovska Nestorovska (mk): Cost-effectiveness analysis of obinutuzumab as first line treatment option for patients with chronic lymphocytic leukemia in Republic of Macedonia. - Zorica Naumovska (Mk): Pharmacoeconomic evaluation of Sorafenib as first-line treatment for Advanced Hepatocellular Carcinoma. - Plenary debate and roundtable discussion - How to manage & afford access to medical innovation? Are we any closer to finding reasonable, patient centric solution? Moderator: Zoltan Kalo (HU) Participants: B. Cukanovic (SRB), J. Furst (SI), L. Garattini (IT), M. Kucan (HR), F. Lamerant (B), R. Likic (HR), V. Sazonov (SI), Lj. Suturkova (MK)

**Describe any regional patient engagement activities.**

Association for the fight against cancer - Borcka Macedonia - 10th National Conference for Breast Cancer, moderator Prof. Ljubica Shuturkova (ISPOR Macedonia), participation Aleksandra Kapedanovska Nestorovska (ISPOR Macedonia)

**Activities organized for students or new professionals.**

**Chapter affiliations with any institutions, universities, government, or associations (other than ISPOR).**

No

**Does your Chapter have any agreements of sponsorship arrangements with any for-profit companies, governments, health authorities, or associations?**

Roche Macedonia, Alkaloid Skopje, NovoNordisk Macedonia, Varus representativ of Merck in Macedonia, Health Insurance Fund.

**Chapter (as a group, not as individual members) formal comments or responses to any government or health authority.**

No

**Chapter Groups**

Research

**HTA in your Chapter's country or region.**

Our Chapter provides training/education in HTA.

Our country/region requires HTA and the Chapter participates in the development/update of national/regional HTA guidelines.

**Is your Chapter officially registered with regional authorities in your country?**

Don't know

**Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?**

No

**Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?**

Yes

**Does the Chapter have a bank account?**

www.ispor-macedonia.org.mk

Yes

**Official organizational email address?**

ispor@ff.ukim.edu.mk

**How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?**

- Collaborations in international ISPOR projects - Educational support in HTA

**3 challenges the Chapter is facing at the start of 2018.**

Elections

Participation in committee for reimbursement drugs

Creating HTA body in regulatory affairs

**Current Chapter members.**

Executive\_Committee\_and\_Chapter\_Members\_ISPOR  
Macedonia 2017.pdf

**CV for the Chapter President.  
Chapter's Annual Work Plan.  
Who prepared this report.**

CV Prof Suturkova Horizont ISPOR 17.pdf  
2018 Regional Chapter Annual Work Plan.pdf  
Prof. Ljubica Shuturkova +38970388824 ljsu@ff.ukim.edu.mk

**FCPA Agreement**

x